Xu Yingjiang, Wu Jiawei, Gao Xiujuan, Li Yiqing, Zheng Hong, Shang Dan
Key Laboratory of Metabolism and Molecular Medicine, The Ministry of Education, Department of Biochemistry and Molecular Biology, Fudan University Shanghai Medical College, Shanghai, China; Department of Interventional Vascular Surgery, Binzhou Medical College Hospital, Binzhou, Shandong Province, China.
Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Ann Vasc Surg. 2020 Apr;64:276-284. doi: 10.1016/j.avsg.2019.09.037. Epub 2019 Oct 18.
An optimal treatment regimen is sought for symptomatic isolated mesenteric artery dissection (IMAD) on the basis of its clinical staging.
From January 2011 to December 2018, 120 patients with symptomatic IMAD from two institutions were collected retrospectively. We reviewed the clinical features, risk factors, computed tomography (CT) images, treatment modalities, and follow-up results to propose a new management strategy based on the clinical stages of the disease.
A total of 120 patients were collected in this study; 77 patients (69 men, 8 women; median age, 52.53 years; range, 39-73 years) who had undergone successful conservative management with antithrombotic agents were included in group A. The remaining 43 patients (34 men, 9 women; median age, 52.63 years; range, 26-66 years) who underwent invasive therapy were included in group B. Significant differences were observed between the two groups with respect to dissection length (50.72 ± 27.72 mm vs. 62 ± 24.3 mm; P = 0.02), true lumen residual diameter (3.31 ± 1.05 mm vs. 2.83 ± 2.05 mm; P = 0.01), and branch involvement (8 and 19, respectively; P < 0.001). Success was achieved in 76.24% (77/101) of patients treated by conservative management with antithrombotic agents in the acute stage; 43 patients underwent invasive interventional therapy in different stages of symptomatic IMAD. In group A, 6 patients had recurrent abdominal pain, three of whom underwent invasive intervention, and the remaining patients improved after conservative treatment. Positive remodeling was observed in 80.33% (49/61) of patients treated with conservative management alone versus 19.67% (12/61) of patients who experienced negative remodeling. Endovascular intervention in group B, CT angiography, or mesenteric angiography yielded complete remodeling in 23 (76.67%, 23/30) patients and evidence of stent restenosis in 7 (23.33%, 7/30) patients. Among the surgical patients, 7 patients showed improvement in the luminal diameter. However, 3 patients with short bowel syndrome require long-term parenteral nutrition.
Conservative management with antithrombotic agents should be a first-line regimen for symptomatic IMAD in the acute stage. If symptoms persist, endovascular intervention is a safe and feasible treatment in the subacute or chronic stage. When peritonitis is present, surgical treatment should be promptly performed, regardless of the disease stage.
根据症状性孤立性肠系膜动脉夹层(IMAD)的临床分期,寻求最佳治疗方案。
回顾性收集2011年1月至2018年12月来自两家机构的120例症状性IMAD患者。我们回顾了临床特征、危险因素、计算机断层扫描(CT)图像、治疗方式和随访结果,以根据疾病的临床分期提出新的管理策略。
本研究共收集120例患者;A组纳入77例(男69例,女8例;中位年龄52.53岁;范围39 - 73岁)接受抗血栓药物保守治疗成功的患者。其余43例(男34例,女9例;中位年龄52.63岁;范围26 - 66岁)接受侵入性治疗的患者纳入B组。两组在夹层长度(50.72±27.72mm对62±24.3mm;P = 0.02)、真腔残余直径(3.31±1.05mm对2.83±2.05mm;P = 0.01)和分支受累情况(分别为8例和19例;P < 0.001)方面存在显著差异。急性期接受抗血栓药物保守治疗的患者中,76.24%(77/101)取得成功;43例症状性IMAD不同阶段的患者接受了侵入性介入治疗。A组6例患者出现复发性腹痛,其中3例接受了侵入性干预,其余患者经保守治疗后好转。单纯接受保守治疗的患者中80.33%(49/61)出现阳性重塑,而经历阴性重塑的患者为19.67%(12/61)。B组的血管内介入治疗、CT血管造影或肠系膜血管造影使23例(76.67%,23/30)患者实现完全重塑,7例(23.33%,7/30)患者有支架再狭窄证据。手术患者中,7例患者管腔直径有所改善。然而,3例短肠综合征患者需要长期肠外营养。
抗血栓药物保守治疗应作为急性期症状性IMAD的一线治疗方案。如果症状持续,血管内介入治疗在亚急性或慢性期是一种安全可行的治疗方法。出现腹膜炎时,无论疾病处于何阶段,均应立即进行手术治疗。